Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

3 Dividend Stocks That Can Power Your Portfolio for Decades


Holding some top dividend stocks in your portfolio can help you generate recurring income for years. This can bolster your savings for retirement or just give you extra money to help pay bills while you hold on to some great investments. Three stocks that you can potentially rely on for dividend income for decades are AbbVie (NYSE: ABBV)Home Depot (NYSE: HD), and Microsoft (NASDAQ: MSFT). Let's dive in and take a closer look at each one.

Healthcare giant AbbVie should please income-oriented investors with its sizable dividend that currently yields 4.3%. That's the highest one on this list. Plus, the company recently announced that it will be increasing its quarterly dividend payments by 4.7% to $1.55 per share. AbbVie has been doing well and recently raised its adjusted earnings per share (EPS) guidance for the year from a range of $10.86-$11.06 to $11.19-$11.23.

AbbVie has been focusing on what it calls its "non-Humira growth platform" as the company works on developing its business outside of Humira, its top-selling rheumatoid arthritis medication that has lost patent protection and is quickly losing market share. Humira's sales totaled $3.5 billion for the period ended Sept. 30 and were down 36% year over year. But two other immunology drugs, Skyrizi and Rinvoq, look to make up for its revenue in the long run. Last quarter, they generated $3.2 billion in sales combined while growing at rates in excess of 50%.

Continue reading


Source Fool.com

AbbVie Inc. Aktie

177,84 €
0,71 %
Die AbbVie Inc. Aktie steigt heute leicht an, gewinnt 0,71 %.
Uneingeschränkte Unterstützung für AbbVie Inc., ausschließlich Buy-Einschätzungen.
Ein leichtes Potenzial nach oben für AbbVie Inc. mit einem Kursziel von 180 € gegenüber dem aktuellen Kurs von 177.84 €.
Like: 0
Teilen

Kommentare